Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission

Haematologica

Volumn 98, Issue 2, 2013, Pages

  Gorin, Norbert Claude ^a   Labopin, Myriam ^a   Meloni, Giovanna ^b   Pigneux, Arnaud ^c   Esteve, Jordi ^d   Mohty, Mohamad ^e  

^a HÔPITAL SAINT ANTOINE   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Acute myelocytic leukemia; Autografted; First remission; FLT3 ITD; Mutations; NPM1

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INCIDENCE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; RELAPSE; REMISSION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION;

ADULT; BONE MARROW TRANSPLANTATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84875309718     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064436     Document Type: Letter

References (12)

1. Schlenk RF, Dohner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18): 1909-18.
2. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109-20.
3. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011;25(8):1297-304.
4. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998;92(4):1073-90.
5. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332(4):217-23.
6. Hamadari M, Mohty M,Kharfan-Dabaja MA. Reduced intensity conditioning allogeneic hemopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control. 2011;18(4);237-45.
7. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report form the bone marrow transplant survivor study. Blood. 2010;116(17):3129-39.
8. Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, et al. Identical outcome following autologous or allogeneic genoidentical hematopoietic stem cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 (inv 16) or t(8;21) A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(19):3183- 8.
9. Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, et al. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood. 2010;116(17):3157-62.
10. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood. 2006; 107(10):4011-20.
11. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Muccioli G, Viola A, et al. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. Biol Blood Marrow Transplant. 2010;16(7):1018-24.
12. Kronke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, et al. Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol.2011; 29(19):2709-16.